Stephane Bancel sold $29M of MRNA
Chief Executive Officer at Moderna, Inc.. 499,246 shares at an average of $57.52, traded Aug 5, 2026, filed Aug 7, 2026.
Score components
- +25RoleCEO
- +25Trade size$28.7M at market
- 0Share of holdings soldSold 7.5% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001682852-26-000153, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Aug 5, 2026 | MOption exercise Common Stock10b5-1 | +499,246 | $19.15 | $9.6M | 6,687,037 | Aug 7, 2026 |
| Aug 5, 2026 | SOpen-market sale Common Stock10b5-1 | -147,473 | $56.21 | $8.3M | 6,539,564 | Aug 7, 2026 |
| Aug 5, 2026 | SOpen-market sale Common Stock10b5-1 | -124,838 | $56.96 | $7.1M | 6,414,726 | Aug 7, 2026 |
| Aug 5, 2026 | SOpen-market sale Common Stock10b5-1 | -39,891 | $58.12 | $2.3M | 6,374,835 | Aug 7, 2026 |
| Aug 5, 2026 | SOpen-market sale Common Stock10b5-1 | -187,044 | $58.79 | $11M | 6,187,791 | Aug 7, 2026 |
| Aug 6, 2026 | MOption exercise Common Stock10b5-1 | +252,469 | $19.15 | $4.8M | 6,440,260 | Aug 7, 2026 |
| Aug 5, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -370,853 | $0.00 | $0 | 187,541 | Aug 7, 2026 |
| Aug 5, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -128,393 | $0.00 | $0 | 64,928 | Aug 7, 2026 |
| Aug 6, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -187,541 | $0.00 | $0 | 0 | Aug 7, 2026 |
| Aug 6, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -64,928 | $0.00 | $0 | 0 | Aug 7, 2026 |
Related signals
Other insiders at Moderna, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 25Weak | Moderna, Inc. | Stephen Hoge President | $12M 80,575 shares | -5% | |
| 37Weak | Moderna, Inc. | James M Mock Chief Financial Officer | $4.7M 34,836 shares | -37% | |
| 13Weak | Moderna, Inc. | Shannon Thyme Klinger Chief Legal Officer | $486k 3,471 shares | -4% | |
| 10Weak | Moderna, Inc. | Stephen Hoge President | $3.6M 53,336 shares | -3% | |
| 18Weak | Moderna, Inc. | Stephen Hoge President | $2.7M 53,336 shares | -3% | |
| 6Weak | Moderna, Inc. | Shannon Thyme Klinger Chief Legal Officer | $174k 3,471 shares | -5% | |
| 52Moderate | Moderna, Inc. | Noubar Afeyan director | $434k 9,263 shares | -70% | |
| 25Weak | Moderna, Inc. | Stephen Hoge President | $2.6M 53,336 shares | -3% | |
| 11Weak | Moderna, Inc. | Abbas Hussain director | $265k 5,682 shares | -32% | |
| 14Weak | Moderna, Inc. | Shannon Thyme Klinger Chief Legal Officer | $726k 13,885 shares | -19% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.